Ross W Paterson
Overview
Explore the profile of Ross W Paterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2629
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leckey C, Coulton J, Giovannucci T, He Y, Aslanyan A, Laban R, et al.
Brain Commun
. 2024 May;
6(3):fcae132.
PMID: 38707707
Neurofilament light chain is an established marker of neuroaxonal injury that is elevated in CSF and blood across various neurological diseases. It is increasingly used in clinical practice to aid...
2.
Biesbroek J, Coenen M, DeCarli C, Fletcher E, Maillard P, Barkhof F, et al.
Alzheimers Dement
. 2024 Mar;
20(4):2980-2989.
PMID: 38477469
Introduction: White matter hyperintensities (WMH) are associated with key dementia etiologies, in particular arteriolosclerosis and amyloid pathology. We aimed to identify WMH locations associated with vascular risk or cerebral amyloid-β...
3.
Coenen M, Biessels G, DeCarli C, Fletcher E, Maillard P, Barkhof F, et al.
Neuroimage Clin
. 2023 Nov;
40:103547.
PMID: 38035457
Introduction: The spatial distribution of white matter hyperintensities (WMH) on MRI is often considered in the diagnostic evaluation of patients with cognitive problems. In some patients, clinicians may classify WMH...
4.
Hallqvist J, Pinto R, Heywood W, Cordey J, Foulkes A, Slattery C, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37762058
As disease-modifying therapies are now available for Alzheimer's disease (AD), accessible, accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to develop a mass spectrometry-based urine test...
5.
Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease
Mok T, Nihat A, Majbour N, Sequeira D, Holm-Mercer L, Coysh T, et al.
Brain
. 2023 Mar;
146(6):2570-2583.
PMID: 36975162
Human prion diseases are remarkable for long incubation times followed typically by rapid clinical decline. Seed amplification assays and neurodegeneration biofluid biomarkers are remarkably useful in the clinical phase, but...
6.
Coenen M, Kuijf H, Huenges Wajer I, Duering M, Wolters F, Fletcher E, et al.
Alzheimers Dement
. 2022 Dec;
19(6):2420-2432.
PMID: 36504357
Introduction: Impact of white matter hyperintensities (WMH) on cognition likely depends on lesion location, but a comprehensive map of strategic locations is lacking. We aimed to identify these locations in...
7.
Horie K, Barthelemy N, Spina S, VandeVrede L, He Y, Paterson R, et al.
Nat Med
. 2022 Nov;
28(12):2547-2554.
PMID: 36424467
Despite recent advances in fluid biomarker research in Alzheimer's disease (AD), there are no fluid biomarkers or imaging tracers with utility for diagnosis and/or theragnosis available for other tauopathies. Using...
8.
Keshavan A, OShea F, Chapman M, Hart M, Lunn M, Paterson R, et al.
Pract Neurol
. 2022 Mar;
22(4):285-294.
PMID: 35301255
Although cerebrospinal fluid (CSF) biomarker testing is incorporated into some current guidelines for the diagnosis of dementia (such as England's National Institute for Health and Care Excellence (NICE)), it is...
9.
Balendra R, North M, Kumar G, Qutab S, Raouf H, Delamont S, et al.
J Neuroophthalmol
. 2022 Feb;
42(2):e459-e462.
PMID: 35213425
No abstract available.
10.
Ziff O, Ashton N, Mehta P, Brown R, Athauda D, Heaney J, et al.
J Neurochem
. 2022 Feb;
161(2):146-157.
PMID: 35137414
SARS-CoV-2 infection can damage the nervous system with multiple neurological manifestations described. However, there is limited understanding of the mechanisms underlying COVID-19 neurological injury. This is a cross-sectional exploratory prospective...